search
Back to results

Energy Expenditure From ECAL Indirect Calorimeter in a Multicomponent Weight Management Service (ECAL)

Primary Purpose

Obesity, Severe Obesity, Sleep Apnoea

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
ECAL Indirect Calorimeter
Diet, exercise & behaviour modification therapy
Sponsored by
University of Liverpool
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring weight management, obesity, severe obesity, structured dietary intervention, calorie restriction, indirect calorimetry, resting energy expenditure, resting metabolic rate, respiratory quotient, substrate oxidation, glycemic variability, insulin sensitivity, peripheral neuropathy

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • BMI > or equivalent to 30 kg/m2 to - 60 kg/m2
  • Stable weight (change of <5% within 12 weeks before screening based on medical history)
  • Subjects are well-motivated, capable and willing to learn how to undergo indirect calorimetry testing
  • Willing and able to adhere to prohibitions and restrictions specified within this protocol

For Subjects participating in the glycaemic variability sub-study:

  • Subject understands instructions on the use of continuous glucose monitor sensor and is willing to undergo appropriate training and testing

Exclusion Criteria:

  • Taking weight loss medication within 12 weeks prior to randomisation
  • Previous or planned bariatric surgery
  • History of Type 1, Type 2 diabetes mellitus, DKA or diabetes secondary to pancreatitis
  • Has HbA1c > or equal to 6.5% or Fasting Plasma Glucose > or equal to 7.0 mmol/L at screening.

NOTE: a one-time repeat measurement is allowed, if value of HbA1c and/or FPG is not consistent with prior values

  • History of obesity with a known secondary cause (Cushing's disease/syndrome)
  • Oral corticosteroid use (except in the short term use of a 7-10 day course)
  • Ongoing, inadequately controlled thyroid disorder defined as thyroid-stimulating hormone > 6 mIU/litre or < 0.4 mIU/litre
  • History of malignancy within 3 years before screening (or diagnosis of malignancy within this period)
  • estimated glomerular filtration rate < 30 ml/min/1.73m2 on serum testing
  • Alanine aminotransferase level is <2.0 times the upper limit of normal or total bilirubin is >1.5 times the upper limit of normal at screening
  • Other major illness likely to preclude participation in the trial
  • History of glucagonoma
  • A myocardial infarction, unstable angina, revascularisation procedure (stent or bypass graft surgery) or cerebrovascular accident within 12 weeks before screening

Sites / Locations

  • University Hospital Aintree

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

ECAL group

SC group

Arm Description

Intervention group (ECAL) - practitioners and participants receive measured energy information from ECAL indirect calorimeter including resting energy expenditure and respiratory quotient to diagnose, manage and advise on modification of caloric restriction and physical activity level. Energy information also allows participant and practitioner to monitor and compare changes to their metabolic health throughout the duration of intervention.

Standard care (SC) - participants receive standard care (diet, exercise & behaviour modification therapy) as part of the multicomponent weight management intervention within the tier 3 weight management service. Practitioners will rely on standard predictive equations to provide dietary advice and intervention.

Outcomes

Primary Outcome Measures

Magnitude of weight loss (in kg)

Secondary Outcome Measures

Resting metabolic rate (RMR)
The measurement of number of calories that the body burns at rest in 24 hours, expressed as kcal/day
Respiratory Quotient (RQ)
The ratio of carbon dioxide production to oxygen consumption and reflects the relative contribution of fat, carbohydrate, and protein in the oxidation fuel mixture.
Secretion of gut hormones (GLP-1, GIP, PYY)
Secretion of appetite regulating gut hormone (GLP-1, GIP, PYY) in fasting and post-prandial phase
Glycaemic variability
Change from baseline in the swings in blood glucose levels, expressed as the mean amplitude of glycaemic excursion (MAGE)
Insulin sensitivity
Change from baseline in the measure of insulin rise in response to blood sugar levels, expressed as the homeostasis model assessment (HOMA). HOMA estimates steady state beta cell function and insulin sensitivity as percentages of the normal reference population.
Sensory Neuropathy Testing in Prediabetic Obese Individuals
Change from baseline in vibration perception threshold measurement using the neurothesiometer
Douleur Neuropathique en4 Questions (DN4)
Change from baseline in Douleur Neuropathique en4 Questions (DN4) using seven interview questions and three physical tests.
Visual analogue score
Change from baseline in visual analogue score of pain, expressed as Units on a scale of 0 to 100. where 0 is worst possible health and 100 is the best possible health.
modified Total Neuropathy Score
Change from baseline in modified Total Neuropathy Score (mTNS) questionnaire expressed as the average of the five components
Brief Pain Inventory Short Form
Change from baseline in brief pain inventory short form (BPI-SF) scored as the mean of the seven interference items.

Full Information

First Posted
August 13, 2018
Last Updated
July 26, 2023
Sponsor
University of Liverpool
Collaborators
Metabolic Health Solutions UK
search

1. Study Identification

Unique Protocol Identification Number
NCT03638895
Brief Title
Energy Expenditure From ECAL Indirect Calorimeter in a Multicomponent Weight Management Service
Acronym
ECAL
Official Title
Randomised Controlled Trial to Evaluate Impact of Energy Expenditure Information on the Outcome of Weight Loss During a Standardised Multicomponent Weight Management Intervention
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
November 28, 2018 (Actual)
Primary Completion Date
August 25, 2022 (Actual)
Study Completion Date
August 25, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Liverpool
Collaborators
Metabolic Health Solutions UK

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Whether greater weight loss is as a result of a smaller reduction in energy expenditure with caloric restriction is not known. Resting energy expenditure and 24-hour energy expenditure vary substantially between individuals. In some cases, relatively reduced rates of 24h EE predict weight gain in some populations who have high prevalence of obesity. Obese individuals that lose weight experience a decrease in 24-h EE and resting energy expenditure that is lower than predicted based on changes in body composition. Most weight loss studies have found a large individual variation in the amount of weight change, and whether an individual's response to an intervention can be predicted is not clear. Measurements of 24-hour EE in response to fasting may help predict weight loss. The ECAL indirect calorimeter (ECAL) is a validated device purpose-built to provide the practitioner and patient with energy information that allows for more accurate, reliable method of establishing an obese individuals' metabolic profile. The aim of this study is to determine whether providing energy information from ECAL indirect calorimeter as an adjunct to the multicomponent weight management intervention in non-diabetic obese and severely obese individuals would help predict the response of weight loss.
Detailed Description
Weight loss is important to improve overall health and reduce risk of obesity-related comorbidities such as diabetes. Numerous studies performed on individuals with predisposed genetic propensity to obesity who are deemed to be metabolically 'thrifty', require further structured intensification of caloric restriction and change in physical activity in order to achieve weight loss. Whether greater weight loss is as a result of smaller reduction in energy expenditure with calorie restriction is not known. Resting energy expenditure and 24-hour energy expenditure vary substantially between individuals. Obese individuals that lose weight experience a decrease in 24-h EE and resting energy expenditure that is lower than predicted based on changes in body composition. Most weight loss studies have found a large individual variation in the amount of weight change, and whether an individual's response to an intervention can be predicted is not clear. Measurements of 24-hour EE in response to fasting may help predict weight loss. The ECAL indirect calorimeter (ECAL) is a validated device purpose-built to provide the practitioner and patient with energy information that allows for more accurate, reliable method of establishing an obese individuals' metabolic profile. The ECAL device also measures the respiratory quotient (RQ) which is the ratio of the volume of carbon dioxide expired to that of oxygen consumed by the individual for every breath. Previous studies demonstrated variability in role of RQ in predicting weight loss, but individuals who demonstrated an RQ in the lower range (<0.72) were more likely to maintain the weight-loss achieved on a caloric restriction and avoid a weight loss rebound as compared to those with RQ in the higher range (>0.75). This suggests that RQ could prove useful in clinical practice as a prognostic marker for long-term effectiveness of low- and very-low-calorie diets used to induce weight loss. Baltimore Longitudinal Study on Aging shared a similar finding that fasting RQ or respiratory exchange ratio adjusted for age, BMI, and fat free mass was positively related to weight change. The aim of this study is to determine whether providing energy information from ECAL indirect calorimeter as an adjunct to the multicomponent weight management intervention in non-diabetic obese and severely obese individuals would help predict the response of weight loss.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Severe Obesity, Sleep Apnoea
Keywords
weight management, obesity, severe obesity, structured dietary intervention, calorie restriction, indirect calorimetry, resting energy expenditure, resting metabolic rate, respiratory quotient, substrate oxidation, glycemic variability, insulin sensitivity, peripheral neuropathy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Parallel assignment
Masking
ParticipantCare Provider
Masking Description
Double (Participant, Practitioner) Energy expenditure information (resting energy expenditure & respiratory quotient) is withheld from participant and practitioner providing care to participants in the control group.
Allocation
Randomized
Enrollment
51 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ECAL group
Arm Type
Active Comparator
Arm Description
Intervention group (ECAL) - practitioners and participants receive measured energy information from ECAL indirect calorimeter including resting energy expenditure and respiratory quotient to diagnose, manage and advise on modification of caloric restriction and physical activity level. Energy information also allows participant and practitioner to monitor and compare changes to their metabolic health throughout the duration of intervention.
Arm Title
SC group
Arm Type
Placebo Comparator
Arm Description
Standard care (SC) - participants receive standard care (diet, exercise & behaviour modification therapy) as part of the multicomponent weight management intervention within the tier 3 weight management service. Practitioners will rely on standard predictive equations to provide dietary advice and intervention.
Intervention Type
Device
Intervention Name(s)
ECAL Indirect Calorimeter
Intervention Description
The ECAL is an open-circuit portable indirect calorimeter that measures both volume of CO2 expired and O2 consumed using a small mixing chamber. Participants will breathe through a mouthpiece with a nose clip applied whilst lying in a restful and comfortable position for 15 minutes. ECAL device will provide breath-by-breath measurements of the resting energy expenditure and respiratory quotient which will allow both practitioners and participants to monitor their metabolic health and compare the effect of dietary and physical activity intervention over the course of the structured intensive lifestyle intervention (24-weeks).
Intervention Type
Behavioral
Intervention Name(s)
Diet, exercise & behaviour modification therapy
Intervention Description
Standard care (SC) - participants receive standard care (diet, exercise & behaviour modification therapy) as part of the multicomponent weight management intervention within the tier 3 weight management service. Practitioners will rely on standard predictive equations to provide dietary advice and intervention.
Primary Outcome Measure Information:
Title
Magnitude of weight loss (in kg)
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Resting metabolic rate (RMR)
Description
The measurement of number of calories that the body burns at rest in 24 hours, expressed as kcal/day
Time Frame
6 months
Title
Respiratory Quotient (RQ)
Description
The ratio of carbon dioxide production to oxygen consumption and reflects the relative contribution of fat, carbohydrate, and protein in the oxidation fuel mixture.
Time Frame
6 months
Title
Secretion of gut hormones (GLP-1, GIP, PYY)
Description
Secretion of appetite regulating gut hormone (GLP-1, GIP, PYY) in fasting and post-prandial phase
Time Frame
6 months
Title
Glycaemic variability
Description
Change from baseline in the swings in blood glucose levels, expressed as the mean amplitude of glycaemic excursion (MAGE)
Time Frame
6 months
Title
Insulin sensitivity
Description
Change from baseline in the measure of insulin rise in response to blood sugar levels, expressed as the homeostasis model assessment (HOMA). HOMA estimates steady state beta cell function and insulin sensitivity as percentages of the normal reference population.
Time Frame
6 months
Title
Sensory Neuropathy Testing in Prediabetic Obese Individuals
Description
Change from baseline in vibration perception threshold measurement using the neurothesiometer
Time Frame
6 months
Title
Douleur Neuropathique en4 Questions (DN4)
Description
Change from baseline in Douleur Neuropathique en4 Questions (DN4) using seven interview questions and three physical tests.
Time Frame
6 months
Title
Visual analogue score
Description
Change from baseline in visual analogue score of pain, expressed as Units on a scale of 0 to 100. where 0 is worst possible health and 100 is the best possible health.
Time Frame
6 months
Title
modified Total Neuropathy Score
Description
Change from baseline in modified Total Neuropathy Score (mTNS) questionnaire expressed as the average of the five components
Time Frame
6 months
Title
Brief Pain Inventory Short Form
Description
Change from baseline in brief pain inventory short form (BPI-SF) scored as the mean of the seven interference items.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: BMI > or equivalent to 30 kg/m2 to - 60 kg/m2 Stable weight (change of <5% within 12 weeks before screening based on medical history) Subjects are well-motivated, capable and willing to learn how to undergo indirect calorimetry testing Willing and able to adhere to prohibitions and restrictions specified within this protocol For Subjects participating in the glycaemic variability sub-study: Subject understands instructions on the use of continuous glucose monitor sensor and is willing to undergo appropriate training and testing Exclusion Criteria: Taking weight loss medication within 12 weeks prior to randomisation Previous or planned bariatric surgery History of Type 1, Type 2 diabetes mellitus, DKA or diabetes secondary to pancreatitis Has HbA1c > or equal to 6.5% or Fasting Plasma Glucose > or equal to 7.0 mmol/L at screening. NOTE: a one-time repeat measurement is allowed, if value of HbA1c and/or FPG is not consistent with prior values History of obesity with a known secondary cause (Cushing's disease/syndrome) Oral corticosteroid use (except in the short term use of a 7-10 day course) Ongoing, inadequately controlled thyroid disorder defined as thyroid-stimulating hormone > 6 mIU/litre or < 0.4 mIU/litre History of malignancy within 3 years before screening (or diagnosis of malignancy within this period) estimated glomerular filtration rate < 30 ml/min/1.73m2 on serum testing Alanine aminotransferase level is <2.0 times the upper limit of normal or total bilirubin is >1.5 times the upper limit of normal at screening Other major illness likely to preclude participation in the trial History of glucagonoma A myocardial infarction, unstable angina, revascularisation procedure (stent or bypass graft surgery) or cerebrovascular accident within 12 weeks before screening
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
John Wilding, DM FRCP
Organizational Affiliation
University of Liverpool
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Aintree
City
Liverpool
ZIP/Postal Code
L9 7AL
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
29222882
Citation
Wang X, Wang Y, Ding Z, Cao G, Hu F, Sun Y, Ma Z, Zhou D, Su B. Relative validity of an indirect calorimetry device for measuring resting energy expenditure and respiratory quotient. Asia Pac J Clin Nutr. 2018;27(1):72-77. doi: 10.6133/apjcn.032017.02.
Results Reference
background
PubMed Identifier
15173405
Citation
Das SK, Saltzman E, McCrory MA, Hsu LK, Shikora SA, Dolnikowski G, Kehayias JJ, Roberts SB. Energy expenditure is very high in extremely obese women. J Nutr. 2004 Jun;134(6):1412-6. doi: 10.1093/jn/134.6.1412.
Results Reference
background
PubMed Identifier
18506270
Citation
Melo CM, Tirapegui J, Ribeiro SM. [Human energetic expenditure: concepts, assessment methods and relationship to obesity]. Arq Bras Endocrinol Metabol. 2008 Apr;52(3):452-64. doi: 10.1590/s0004-27302008000300005. Portuguese.
Results Reference
background
PubMed Identifier
27848941
Citation
Lam YY, Ravussin E. Indirect calorimetry: an indispensable tool to understand and predict obesity. Eur J Clin Nutr. 2017 Mar;71(3):318-322. doi: 10.1038/ejcn.2016.220. Epub 2016 Nov 16.
Results Reference
background
PubMed Identifier
28902175
Citation
McLay-Cooke RT, Gray AR, Jones LM, Taylor RW, Skidmore PML, Brown RC. Prediction Equations Overestimate the Energy Requirements More for Obesity-Susceptible Individuals. Nutrients. 2017 Sep 13;9(9):1012. doi: 10.3390/nu9091012.
Results Reference
background
PubMed Identifier
19398250
Citation
Alves VG, da Rocha EE, Gonzalez MC, da Fonseca RB, Silva MH, Chiesa CA. Assessement of resting energy expenditure of obese patients: comparison of indirect calorimetry with formulae. Clin Nutr. 2009 Jun;28(3):299-304. doi: 10.1016/j.clnu.2009.03.011. Epub 2009 Apr 23.
Results Reference
background
PubMed Identifier
33762240
Citation
Lim J, Alam U, Cuthbertson D, Wilding J. Design of a randomised controlled trial: does indirect calorimetry energy information influence weight loss in obesity? BMJ Open. 2021 Mar 24;11(3):e044519. doi: 10.1136/bmjopen-2020-044519.
Results Reference
derived

Learn more about this trial

Energy Expenditure From ECAL Indirect Calorimeter in a Multicomponent Weight Management Service

We'll reach out to this number within 24 hrs